Compare GSK plc (GSK) vs IONQ Inc (IONQ) Price & Performance

GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.

The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.

IONQ trades at $39.45, down 4.57% today, showing bearish technical signals with mixed fundamental performance. The company reported strong revenue growth ($130M in 2025, projected $246M in 2026) but significant losses (-$510M net income in 2025). Recent earnings show a pattern of beats and misses, with Q2 2026 missing expectations. Technical indicators show bearish momentum despite some oversold conditions, with key support at $36 and resistance at $41.

Outlook remains speculative with high growth potential but substantial execution risks. Analyst consensus is split with a $62.75 price target suggesting 59% upside, though profitability challenges and cash burn (-$283M operating cash flow in 2025) present significant hurdles. The quantum computing market opportunity is substantial, but IONQ must demonstrate path to profitability to justify current valuations.